Get the latest news and updates
Dr. Jesse Salk is a medical oncologist and a Founder of TwinStrand Biosciences. His research interests lie in studying somatic evolution and the genomic processes that occur on the continuum between “normal”, preneoplastic and cancer, and applying this to knowledge to clinical medicine. He developed the ultra-high accuracy Duplex Sequencing technology with colleagues at the University of Washington, where he completed his medical and graduate degrees as well as clinical training. Since 2017, Dr. Salk has led TwinStrand, applying Duplex Sequencing to new areas of high sensitivity early and residual cancer detection, evolution of drug resistance and genetic toxicology, among other fields. He holds a clinical faculty appointment at the University of Washington and continues to care for cancer patients part time at the VA Puget Sound in Seattle.
Liquid Biopsy Showcase: Twinstrand Biosciences
TwinStrand develops ultrasensitive Duplex Sequencing-based assays for early detection of cancer, residual disease monitoring and genetic toxicology.
Ultrasensitive Minimal Residual Disease Detection By Duplex Sequencing
Duplex Sequencing enables an unprecedented level of NGS accuracy, with error rates below one-in-ten-million. The technology is ideally suited to detection of residual cancer (MRD), where lingering tumor cells are vastly outnumbered by normal cells. Here we present Duplex Sequencing-based MRD data from three clinical studies in acute myeloid leukemia.
The PMWC 2020 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).